Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial

[1] Varga J(2007)Systemic sclerosis: a prototypic multisystem fibrotic disorder J Clin Invest 117 557-67

[2] Abraham D(2003)National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study J Rheumatol 30 958-400

[3] Thomas E(2010)Evidence-based management of rapidly progressing systemic sclerosis Best Pract Res Clin Rheumatol 24 387-27

[4] Symmons DP(2004)TGF-beta signaling and the fibrotic response FASEB J 18 816-4

[5] Brewster DH(2008)Role of PDGF in fibrotic diseases and systemic sclerosis Rheumatology (Oxford) 47 v2-6

[6] Black RJ(2007)Nilotinib (formerly AMN107), a highly selective Bcr-Abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance Blood 110 3540-22

[7] Macfarlane GJ(2008)Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis FASEB J 22 2214-46

[8] Khanna D(2013)Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors Ann Rheum Dis 72 2039-9

[9] Denton CP(2011)Tyrosine kinase inhibitors in the treatment of systemic sclerosis: The difficulty in interpreting proof-of-concept studies Int J Rheumatol 2011 842181-6

[10] Leask A(2011)Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial Ann Rheum Dis 70 1003-51

[1] Varga J(2007)Systemic sclerosis: a prototypic multisystem fibrotic disorder J Clin Invest 117 557-67

[2] Abraham D(2003)National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study J Rheumatol 30 958-400

[3] Thomas E(2010)Evidence-based management of rapidly progressing systemic sclerosis Best Pract Res Clin Rheumatol 24 387-27

[4] Symmons DP(2004)TGF-beta signaling and the fibrotic response FASEB J 18 816-4

[5] Brewster DH(2008)Role of PDGF in fibrotic diseases and systemic sclerosis Rheumatology (Oxford) 47 v2-6

[6] Black RJ(2007)Nilotinib (formerly AMN107), a highly selective Bcr-Abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance Blood 110 3540-22

[7] Macfarlane GJ(2008)Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis FASEB J 22 2214-46

[8] Khanna D(2013)Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors Ann Rheum Dis 72 2039-9

[9] Denton CP(2011)Tyrosine kinase inhibitors in the treatment of systemic sclerosis: The difficulty in interpreting proof-of-concept studies Int J Rheumatol 2011 842181-6

[10] Leask A(2011)Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial Ann Rheum Dis 70 1003-51